However, the initial starting dose was decreased to 905 mg/m2/d, or to 724 mg/m2/d in case of significative adverse events (hypertriglyceridemia, fatigue, aspartate aminotransferase (AST)/alanine aminotransferase (ALT) increase, thrombocytopenia, bilirubin increase, and dry skin). This evidence concerns the gene GPT and Thrombocytopenia.